S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2024
0mins
Source: Benzinga
- U.S. Stock Market: Nasdaq Composite gained 0.1%, Dow rose by 0.19%, and S&P 500 increased by 0.10%.
- Top Headline: ON Semiconductor reported better-than-expected first-quarter results with revenue decline but higher EPS than consensus.
- Equities Trading UP: Deciphera Pharmaceuticals to be acquired by ONO Pharmaceutical, Collective Audience surged due to a partnership, Philips N.V. shares up after settlement and good earnings.
- Equities Trading DOWN: Clever Leaves Holdings to delist, Addex Therapeutics and Annovis Bio down after study results.
- Commodities and Eurozone: Oil down, gold up; European shares mixed, Eurozone indicators fluctuated, Spain's inflation rate increased.
Analyst Views on ANVS
Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 12.50 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.060
Low
8.00
Averages
12.50
High
17.00
Current: 3.060
Low
8.00
Averages
12.50
High
17.00
About ANVS
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
